GH La Pitié Salpêtrière - CHU APHP
Welcome,         Profile    Billing    Logout  
 26 Trials 
12 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DUBREUIL, Olivier
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
AQUATIC, NCT04217447: Assessment of Quitting Versus Using Aspirin Therapy in Patients Treated with Oral Anticoagulation for Atrial Fibrillation or Other Indication with Stabilized Coronary Artery Disease

Terminated
3
874
Europe
OAC + Aspirin 100mg od, OAC + placebo of Aspirin 100mg od
University Hospital, Brest, Bayer
Coronary Artery Disease
10/24
10/24
SCARCE, NCT03519295 / 2017-003185-27: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Active, not recruiting
2
99
Europe
MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil
GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG
Anal Cancer
02/23
12/24
MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.

Active, not recruiting
2
307
Europe
Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan
GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca
Metastatic Pancreatic Adenocarcinoma
07/23
12/24
TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Recruiting
2
73
Europe
Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab
UNICANCER, Servier
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
10/26
10/28
LOGICAN, NCT05476796 / 2022-000273-81: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Recruiting
2
118
Europe
Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO
UNICANCER, Servier
Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/26
01/27
COBRAF, NCT05639413: A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Recruiting
N/A
400
Europe
Collection of blood samples
UNICANCER, Pierre Fabre Medicament
Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
07/27
07/28
Bachet, Jean-Baptiste
STRATEGIC-1, NCT01910610 / 2013-001928-19: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Active, not recruiting
3
464
Europe, RoW
FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab
GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche
Colorectal Cancer Metastatic
07/23
12/24
OPTIPRIME, NCT03584711: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

Active, not recruiting
2
118
Europe, RoW
FOLFOX + panitumumab
Federation Francophone de Cancerologie Digestive, Amgen
Metastatic Colorectal Cancer
12/24
12/24
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
LAP-NET1, NCT05546853: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Active, not recruiting
1
43
Europe
NP137, Oxaliplatin, Irinotecan, Calcium levofolinate, 5 FU
University Hospital, Grenoble, NETRIS Pharma
Pancreatic Ductal Adenocarcinoma
12/24
06/25
COBRAF, NCT05639413: A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Recruiting
N/A
400
Europe
Collection of blood samples
UNICANCER, Pierre Fabre Medicament
Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
07/27
07/28
DOAT, Solène
No trials found
MORYOUSSEF, Frederick
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DUBREUIL, Olivier
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
AQUATIC, NCT04217447: Assessment of Quitting Versus Using Aspirin Therapy in Patients Treated with Oral Anticoagulation for Atrial Fibrillation or Other Indication with Stabilized Coronary Artery Disease

Terminated
3
874
Europe
OAC + Aspirin 100mg od, OAC + placebo of Aspirin 100mg od
University Hospital, Brest, Bayer
Coronary Artery Disease
10/24
10/24
SCARCE, NCT03519295 / 2017-003185-27: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Active, not recruiting
2
99
Europe
MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil
GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG
Anal Cancer
02/23
12/24
MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.

Active, not recruiting
2
307
Europe
Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan
GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca
Metastatic Pancreatic Adenocarcinoma
07/23
12/24
TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Recruiting
2
73
Europe
Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab
UNICANCER, Servier
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
10/26
10/28
LOGICAN, NCT05476796 / 2022-000273-81: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Recruiting
2
118
Europe
Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO
UNICANCER, Servier
Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/26
01/27
COBRAF, NCT05639413: A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Recruiting
N/A
400
Europe
Collection of blood samples
UNICANCER, Pierre Fabre Medicament
Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
07/27
07/28
Bachet, Jean-Baptiste
STRATEGIC-1, NCT01910610 / 2013-001928-19: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Active, not recruiting
3
464
Europe, RoW
FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab
GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche
Colorectal Cancer Metastatic
07/23
12/24
OPTIPRIME, NCT03584711: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

Active, not recruiting
2
118
Europe, RoW
FOLFOX + panitumumab
Federation Francophone de Cancerologie Digestive, Amgen
Metastatic Colorectal Cancer
12/24
12/24
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
LAP-NET1, NCT05546853: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Active, not recruiting
1
43
Europe
NP137, Oxaliplatin, Irinotecan, Calcium levofolinate, 5 FU
University Hospital, Grenoble, NETRIS Pharma
Pancreatic Ductal Adenocarcinoma
12/24
06/25
COBRAF, NCT05639413: A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Recruiting
N/A
400
Europe
Collection of blood samples
UNICANCER, Pierre Fabre Medicament
Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
07/27
07/28
DOAT, Solène
No trials found
MORYOUSSEF, Frederick
No trials found

Download Options